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AbstrAct:
Based on the microRNA (miRNA) expression signatures of hypopharyngeal and 
esophageal squamous cell carcinoma, we found that miR-1   was  significantly 
down-regulated in cancer cells. In this study, we investigated the functional 
significance  of  miR-1 in head and neck squamous cell carcinoma (HNSCC) cells 
and  identified  miR-1-regulated novel cancer pathways. Gain-of-function studies 
using  miR-1  revealed  significant  decreases  in  HNSCC  cell  proliferation,  invasion, 
and migration. In addition, the promotion of cell apoptosis and cell cycle arrest 
was demonstrated following miR-1 transfection of cancer cells. A search for the 
targets of miR-1 revealed that transgelin 2 (TAGLN2) was directly regulated by 
miR-1. Silencing of TAGLN2  significantly  inhibited  cell  proliferation  and  invasion 
in HNSCC cells. Down-regulation of miR-1 and up-regulation of TAGLN2 were 
confirmed in HNSCC clinical specimens. Our data indicate that TAGLN2 may have 
an oncogenic function and may be regulated by miR-1, a tumor suppressive miRNA 
in  HNSCC.  The  identification  of  novel  miR-1-regulated cancer pathways could 
provide new insights into potential molecular mechanisms of HNSCC carcinogenesis.
IntroductIon
Head and neck squamous cell carcinoma (HNSCC) 
constitutes the sixth most common malignancy 
worldwide [1]. In spite of considerable advances in 
multimodality therapy including surgery, radiotherapy, 
and  chemotherapy,  the  overall  five  year  survival  rate 
for patients with this type of cancer is among the 
lowest of all major cancer types and has not improved 
during the last decade [2]. Local tumor recurrence and 
distant metastasis after conventional therapy appear to 
be major contributing factors for restricted survival of 
HNSCC patients. Therefore, understanding the molecular 
oncogenic pathways underlying HNSCC would help to 
improve diagnosis, approaches to therapy, and prevention 
of the disease.
MicroRNAs (miRNAs) are endogenous, short, non-
coding RNA molecules which regulate gene expression 
by translational repression or degradation of mRNA in a 
sequence-specific manner [3]. Bioinformatic prediction 
indicates that miRNAs regulate more than 30% of the 
protein coding genes [4]. It is estimated that approximately 
1,000 miRNAs exist in the vertebrate genome. At this 
time, 1,048 human miRNAs are registered at miRBase 
release  16.0  (http://microrna.sanger.ac.uk/).  A  growing 
body of evidence suggests that miRNAs are aberrantly 
expressed in many human cancers, and that they play 
significant roles in carcinogenesis and cancer progression Oncotarget 2011; 2:  29 - 42 30 www.impactjournals.com/oncotarget
[5].  miRNAs  can  be  divided  into  two  classes:  those 
which are oncogenic miRNAs and those which are tumor 
suppressive miRNAs. Up-regulated miRNAs could act 
as oncogenes by negatively regulating tumor suppressor 
genes, while down-regulated miRNAs could function as 
tumor suppressors by repressing oncogenes [6,7]. 
Studies of tumor suppressive miRNAs and searches 
for their target genes are important for our understanding 
of miRNA-regulated cancer pathways, including those 
specific  miRNAs  altered  in  HNSCC  [8-10].  Recently, 
our miRNA profiles showed that miR-133a was down-
regulated in cancer cells and that miR-133a had tumor 
suppressive  functions  [11-13].  Interestingly,  miR-1 
and  miR-133a are located on the same chromosomal 
locus, forming a so called cluster. miR-1 and miR-133a 
are expressed in muscle and might be the most studied 
miRNAs in skeletal and cardiac muscle development 
[14,15].
miR-1 was also down-regulated in our miRNA 
screening of hypopharyngeal and esophageal squamous cell 
carcinoma [13,16]. However, the functional significance 
of miR-1 has not been clarified in HNSCC. The aim of this 
study was to investigate the function of miR-1 in HNSCC 
cell lines and to identify miR-1-regulated cancer pathways. 
For target genes searches of miR-1 in HNSCC cells, we 
performed genome-wide gene expression analysis. We 
focused on transgelin 2 (TAGLN2) as a candidate target of 
miR-1, as it was among the most down-regulated genes. 
Insight into the association between tumor suppressive 
miRNA and their target oncogene networks could enhance 
our understanding of the molecular mechanism of HNSCC 
carcinogenesis.
Figure 1: Gain-of-function studies using miR-1 transfected Hnscc cell lines (Hsc3 and Fadu). (A) Cell growth as revealed 
by the XTT assay after 72 hr [above] and 96 hr [below]. (B) HSC3 cell migration activity (wound healing assay).(C) Cell invasion activity ( 
Matrigel invasion assay) in HSC3 and FaDu transfected with miR-1. *P < 0.05   
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results
effect of mir-1 transfection on cell proliferation, 
migration, and invasion in Hnscc cell lines
To determine the function of miR-1, we performed 
gain-of-function analysis using miR-1 transfectants. The 
XTT assay showed statistically significant inhibition of 
cell proliferation in miR-1 transfectants in comparison 
with miRNA controls after 72 hr and 96 hr. For example, 
after 72 hr, both miR-1  transfected  HSC3  and  FaDu 
cultures grew only ~42% as much as control cultures (both 
P < 0.05, Figure 1A, top), while after 96 hr, proliferation 
fell to 23% and 9% of controls, respectively, (both P < 
0.05, Figure 1A, bottom). Wound healing assays of miR-
1-transfected HSC3 demonstrated that cell migration was 
significantly inhibited to 5% that of control (P < 0.05; 
Figure 1B).The Matrigel invasion assay showed that the 
number of invading cells was significantly decreased in 
miR-1 transfectants. Relative to control values (100%), 
the percentages of invading HSC3 and FaDu cells were 
only 45% and 27.1%, respectively (both P < 0.05; Figure 
1C).
Figure 2: effect of miR-1 transfection on cell apoptosis and cell cycle. (A) The representative quadrant figures of 
miRNA-control, or miR-1 transfectants in HSC3 [above] and FaDu [below] cells are shown. The bar chart shown on 
the right of each quadrant indicates the ratio of the early apoptotic cell fraction in miR-1 transfectants in comparison 
with miRNA-control transfectant. The data for the early apoptotic cell fraction is expressed as the relative value of 
the average expression of the miRNA-control transfectant. * P < 0.05. (B) The typical figures of cell cycle analysis 
of miRNA-control, or miR-1 transfectants are shown. The bar chart shown on the right of each figures represents the 
percentage of the cells in G0/G1, S, or G2/M phase as indicated. * P < 0.05.
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effect of mir-1 transfection on cell apoptosis and 
cell cycle in Hnscc cell lines
Cell apoptosis in miR-1 transfected cells was 
assessed by flow cytometry. The fraction of early apoptotic 
cells  significantly  increased  in  miR-1 transfectants 
approximately  3-fold  in  HSC3  and  12-fold  in  FaDu 
compared with controls (both P < 0.05, Figure 2A). We 
also  confirmed  induction  of  apoptosis  approximately 
4-fold  in  FaDu  by  ectopic  miR-1 performing TUNEL 
assay (data not shown). As for cell cycle distribution, 
cells in G0/G1 phase were significantly greater in miR-1 
transfectant than those in the control (Figure 2B). These 
results suggest that ectopic miR-1 expression induces G0/
G1 arrest in both HNSCC cell lines
table 1: down-regulated genes in mir-1 transfectants
HSC3  FaDu  Average 
1 27230 SERP1 
stress-associated endoplasmic 
reticulum protein 1 
-1.61  -2.54  -2.08  +
2 8407 TAGLN2  transgelin 2  -1.77  -2.03  -1.90  +
3 23446 SLC44A1  solute carrier family 44, member 1  -1.62  -1.96  -1.79  +
4 9542 NRG2  neuregulin 2  -1.87  -1.60  -1.73  -
5 23531 MMD 
monocyte to macrophage 
differentiation-associated 
-1.38  -2.03  -1.71  +
6 5756 TWF1 
twinfilin, actin-binding protein, 
homolog 1 (Drosophila) 
-1.57  -1.69  -1.63  +
7 5819 PVRL2 
poliovirus receptor-related 2 
(herpesvirus entry mediator B) 
-1.08  -2.02  -1.55  +
8 201895 C4orf34  chromosome 4 open reading frame 34  -1.53  -1.50  -1.52  +
9 3927 LASP1  LIM and SH3 protein 1  -1.33  -1.61  -1.47  +
10 7106 TSPAN4  tetraspanin 4  -1.26  -1.63  -1.45  +
11 4860 NP  nucleoside phosphorylase  -1.40  -1.48  -1.44  +
12 5757 PTMA  prothymosin, alpha  -1.33  -1.49  -1.41  +
13 84650 EBPL  emopamil binding protein-like  -1.48  -1.34  -1.41  +
14 303 ANXA2P1  annexin A2 pseudogene 1  -1.65  -1.15  -1.40  -
15 8683 SFRS9 
splicing factor, arginine/serine-
rich 9 
-1.36  -1.38  -1.37  +
16 359845 FAM101B 
family with sequence similarity 101, 
member B 
-1.03  -1.68  -1.36  +
17 726 CAPN5  calpain 5  -1.46  -1.23  -1.35  +
18 64420 SUSD1  sushi domain containing 1  -1.25  -1.44  -1.34  +
19 9881 TRANK1 
tetratricopeptide repeat and ankyrin 
repeat containing 1 
-1.24  -1.40  -1.32  -
20 79794 C12orf49 chromosome 12 open reading frame 49 -0.98  -1.64  -1.31  +
miR-1 
target 
site
No.  Gene Symbol  Gene Name 
Log2 ratio 
Entrez Gene IDOncotarget 2011; 2:  29 - 42 33 www.impactjournals.com/oncotarget
Gene  expression  profiling  identifies  down-
regulated genes in mir-1 transfectants
To investigate candidate molecular targets of miR-
1 in HNSCC cells, we examined the effect of miR-1 on 
protein coding genes. Mature miR-1 was transiently 
transfected  into  HSC3  and  FaDu  cells,  with  negative 
miRNA transfection used as a control. Comprehensive 
gene expression analysis (see Methods) clearly showed 
changes in gene expression patterns between miR-1 and 
negative-control transfectants. To identify candidate 
miR-1 target genes, a cut-off of value less than -2.00-fold 
was applied to the array data. This filter resulted in the 
identification of 59 genes that were significantly down-
regulated upon miR-1  transfection  in  both  HSC3  and 
FaDu cells (top 20 genes are shown in Table 1). Entries 
from the microarray data were approved by the Gene 
Expression Omnibus (GEO), and were assigned GEO 
accession number GSE24782. The 3’ UTR of these down-
regulated genes were examined for miR-1 target sites 
using the TargetScan database. Of the top 20 putative gene 
targets, 17 genes contained miR-1 target sites. 
tAGln2 is a target of post-transcriptional 
repression by mir-1
TAGLN2 was the second ranked candidate gene in 
the genome-wide gene expression analysis. We focused 
on  TAGLN2 and not the top ranked gene (SERP1), 
because the latter was not reported to be associated with 
carcinoma. The expression level of TAGLN2 mRNA was 
significantly decreased in both HNSCC cell lines (HSC3 
and FaDu) transfected with miR-1 (Figure 3, upper). The 
protein expression levels were also markedly reduced in 
miR-1 transfectants (Figure 3, lower). HSC3 cells were 
used to determine the mechanism of miR-1 suppression of 
TAGLN2 expression. The TargetScan database identified 
three  putative  target  sites  in  the  3’UTR  of  TAGLN2 
(Figure 4, upper). A luciferase reporter assay confirmed 
the  3’UTR  of  TAGLN2 as the actual target of miR-1. 
Luciferase activity was significantly decreased by the full 
length 3’UTR of TAGLN2 as well as by all three predicted 
targeting sites of miR-1 (positions 71-77, 185-191, and 
348-354 in the 3’UTR of TAGLN2) (Figure 4, lower).
effects of tAGln2 silencing on cell proliferation, 
apoptosis, migration, and invasion in Hnscc cell 
lines
Loss-of-function assays using siRNA analysis were 
performed to examine the oncogenic function of TAGLN2. 
We asked whether si-TAGLN2 reduced both mRNA and 
protein expression levels of si-TAGLN2 transfectants in 
HSC3 and FaDu. Both TAGLN2 mRNA and TAGLN2 
protein were reduced following a 72 hr transfection with 
si-TAGLN2 (Figure 5). The XTT assay revealed significant 
cell growth inhibition in si-TAGLN2 transfected cells after 
96 hr transfection. Specifically, with si-TAGLN2_1 and si-
TAGLN2_2,HSC3 proliferation was inhibited 
60.0%  and  76.3%,  respectively  while  FaDu  was 
inhibited  76.8%  and  69.2%,  respectively  (Figure  6A). 
Significant  inhibition  was  not  demonstrated  after  72 
hr transfection (data not shown). The fraction of early 
Figure 3: regulation of TAGLN2  expression in miR-
1  transfectants.  (A) RT-PCR revealed that TAGLN2 mRNA 
was markedly repressed in miR-1 transfectants compared with 
the miRNA-controls. * P < 0.05 (B) Western blots revealed that 
TAGLN2 protein was also decreased in miR-1.
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apoptotic HSC3 cells was increased in the two si-TAGLN2 
transfectants  from  1.00  in  controls  to  2.91  ±  0.32  (si-
TAGLN2_1) and 3.76 ± 0.23 (si-TAGLN2_2)(Figure 6B). 
Similarly, with FaDu cells, apoptosis increased from 1.00 
(control) to 2.83 ± 0.03 (si-TAGLN2_1) and 4.13 ± 0.04 
(si-TAGLN2_2). The wound healing assay demonstrated 
that HSC3 cell migration was inhibited by 59.6 ± 3.2% 
(si-TAGLN2_1)  and  54.9  ±  3.7  (si-TAGLN2_2) (Figure 
6C). Finally, the Matrigel invasion assay showed that the 
number of invading cells was significantly decreased in 
si-TAGLN2 HSC3 transfectants relative to controls: 41.1 
± 3.5% (si-TAGLN2_1) and 54.5 ± 14.5 (si-TAGLN2_2). 
Similarly, FaDu transfectants were inhibited 29.4 ± 2.2% 
(si-TAGLN2_1) and 21.8 ± 1.3%(si-TAGLN2_2) (Figure 
6D).
tAGln2 mrnA and mir-1 expression in Hnscc 
clinical specimens
Data  characterizing  20  HNSCC  patients  are 
presented in Table 2. The expression levels of miR-1 were 
significantly down-regulated in clinical HNSCC specimen 
compared with adjacent normal tissues (P = 0.0276, Figure 
7A). Conversely, TAGLN2 mRNA was significantly up-
regulated in tumor tissues (P = 0.0209, Figure 7B). 
Figure 4: three target sites for miR-1 in the TAGLN2 3’UTR were identified with the TargetScan database. A luciferase 
reporter assay using the vector encoding full-length 3’UTR and respective putative target sites of TAGLN2 mRNA. The Renilla luciferase 
values were normalized by firefly luciferase values. * P < 0.05
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table 2: clinical features of Hnscc patients.
No. Gender Age Location Differentiation T N M Stage
1 Male 82 Tongue Well 1 0 0 I
2 Male 64 Tongue Moderate 3 2 0 IVA
3 Male 66 Tongue Well 2 0 0 II
4 Male 70 Tongue Well 1 0 0 I
5 Male 67 Oral floor Moderate 3 2 0 IVA
6 Male 47 Oral floor Moderate 1 2 0 IVA
7 Male 69 Larynx Well 3 0 0 III
8 Male 73 Larynx Well 2 0 0 II
9 Male 80 Larynx Poor 3 2 0 IVA
10 Male 59 Oropharynx Poor 4 0 0 IVA
11 Male 76 Oropharynx Poor 2 0 0 II
12 Male 55 Oropharynx Moderate 3 2 0 IVA
13 Female 83 Oropharynx Moderate 1 0 0 I
14 Male 74 Oropharynx Well 2 0 0 II
15 Male 66 Hypopharynx Moderate 2 2 0 IVA
16 Male 71 Hypopharynx Poor 2 2 0 IVA
17 Male 49 Hypopharynx Moderate 2 2 0 IVA
18 Male 71 Hypopharynx Poor 4 2 0 IVA
19 Male 66 Hypopharynx Well 4 2 0 IVA
20 Male 66 Hypopharynx Moderate 3 2 0 IVAOncotarget 2011; 2:  29 - 42 36 www.impactjournals.com/oncotarget
dIscussIon
Aberrant expression of miRNAs and dysregulated 
gene expression of tumor suppressors and oncogenes 
have been associated with the development of human 
cancers.  For  the  purpose  of  identification  of  cancer-
related miRNAs, we determined miRNA expression 
signatures in hypopharyngeal and esophageal squamous 
cell carcinomas. Those profiles showed that miR-1 was 
significantly  down-regulated  and  had  the  features  of  a 
candidate  tumor  suppressor  [13,16].  Other  researchers 
have found that miR-1 was down-regulated in other 
types  of  cancer[17-20].  Ectopic  expression  of  miR-
1 inhibited cancer cells in hepatocellular carcinoma, 
rhabdomyosarcoma, and lung cancer[18-20]. 
Interestingly,  miR-1-1/miR-133a-2,  miR-1-2/miR-
133a-1, and miR-206/miR-133b are clustered on three 
different chromosomal regions in the human genome, 
Figure 5: effect of TAGLN2 silencing on Hnscc cells. (A) RT-PCR revealed that TAGLN2 mRNA was markedly repressed in 
si-TAGLN2 transfectants compared with the si-controls. * P < 0.0001 (B) Western blot revealed that TAGLN2 protein was also decreased in 
si-TAGLN2.
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20q13.33,  18q11.2,  and  6p12.1,  respectively.  miR-206 
is similar to miR-1 in terms of expression and function 
but differs from the miR-1 sequence by four nucleotides. 
miR-133a-1 and miR-133a-2 possess identical mature 
sequences. miR-133b differs from miR-133a by a single 
nucleotide  at  the  3’  end  [15].  Regarding  miR-133a in 
human cancers, our previous studies demonstrated that 
miR-133a functions as a tumor suppressor and targets 
multiple oncogenes, such as FSCN1[12,13,21],  LASP1 
[22],  CAV1  [23]  and  GSTP1 [24,25]. Other studies 
revealed that miR-133a was reduced in pancreatic ductal 
adenocarcinoma [26], colorectal carcinoma [27], tongue 
squamous cell carcinoma [28], and rhabdomyosarcoma 
[29]. It is clear that regulation of target genes by miR-133a 
is deeply involved in the modulation of cancer cells.
In this study, our data revealed that restoration of 
miR-1 expression suppressed cell proliferation, migration, 
and invasion and promoted apoptosis and cell cycle arrest 
in HNSCC cells. Our results and those of past reports 
indicate that miR-1 frequently functions as a tumor 
suppressor in human cancer.
miRNAs control the expression of target genes 
which contribute to cancer development and progression. 
Because it is important to identify novel miRNA-mediated 
cancer pathways, we investigated miR-1-regulated 
oncogenic targets. We adopted a method of genome-wide 
gene expression analysis in two HNSCC cell lines, using 
miR-1 transfectants to identify targets. This strategy has 
led to the identification of tumor suppressive miRNAs 
targets  [12,13,16,21,23,25].  Published  articles  revealed 
that  miR-1  mediates cell apoptosis, targeting BCL2 in 
cardiac muscles [30]. In cancer, miR-1 induced apoptosis 
through repression of Mcl-1 in lung cancer [19]. miR-1 
also targets c-Met in rhabdomyosarcoma [20]. However, 
to our knowledge, the target gene of miR-1 in HNSCC 
was unknown. TAGLN2 was significantly down-regulated 
Figure 6: loss-of-function studies using si-TAGLN2 transfected Hnscc cell lines. (A) Cell growth as revealed by the XTT 
assay. * P < 0.0001, ** P = 0.0003 (B) Apoptosis assay determined by flow cytometry. The apoptosis assay data are shown as normalized ratios 
in the histogram. * P = 0.0015, ** P = 0.002, *** P < 0.0001 (C) Cell migration activity (wound healing assay) in HSC3. * P < 0.0001; (D) Cell 
invasion activity ( Matrigel invasion assay) transfected with si-TAGLN2. * P < 0.0035, ** P < 0.0153, *** P < 0.0001
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by ectopic expression of miR-1 in HNSCC cell lines in our 
present study. The luciferase reporter assay revealed that 
TAGLN2 contains three sites that actually bind miR-1. This 
is the first report demonstrating that tumor suppressive 
miR-1 directly regulates TAGLN2 in HNSCC cells.
TAGLN2 is a member of the calponin family 
of actin-binding proteins. TAGLN2 is a homolog of 
the  protein  TAGLN  [31].  Though  over-expression  of 
TAGLN2 was observed in hepatocellular carcinoma, lung 
adenocarcinoma, and pancreatic cancer [32-35], analysis 
of TAGLN2 in HNSCC has not yet been reported. Here, 
we  demonstrated  significant  up-regulation  of  TAGLN2 
expression in HNSCC clinical specimens. It was 
demonstrated that increasing TAGLN2 expression was 
correlated with lymph node metastasis, distant metastasis, 
and  the  TNM  classification  in  colorectal  cancer  [36]. 
Those results support the present loss-of-function analysis 
with si-TAGLN2, confirming that TAGLN2 mediates cell 
migration and invasion, suggesting that this gene may 
have an oncogenic function. However, it is still unknown 
how TAGLN2, an actin-binding protein, contributes to cell 
apoptosis, which should be clarified by further analysis.
In conclusion, our results show that restoration of 
miR-1 in cancer cells inhibits cell proliferation, invasion, 
and migration, supporting the hypothesis that miR-1 
functions as a tumor suppressor in HNSCC. Our data also 
indicate that TAGLN2 may have an oncogenic function 
which is directly regulated by miR-1. The identification 
of novel miR-1-regulated cancer pathways could provide 
new insights into potential molecular mechanisms and 
applications to diagnosis, therapy, and prevention of the 
disease.
MetHods
Hnscc cell culture
Human  HNSCC  cell  lines  (HSC3,  derived  from 
a lymph node metastasis of tongue squamous cell 
carcinoma, and FaDu, derived from a primary lesion of 
hypopharyngeal squamous cell carcinoma) were provided 
by the American Type Culture Collection (ATCC, 
Manassas, VA, USA). Both cell lines were grown in 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture 
F-12 Ham (DMEM/F-12) supplemented with 10% fetal 
bovine serum in a humidified atmosphere containing 5% 
CO2 at 37°C.
rnA isolation
Total  RNA  was  isolated  using  TRIzol  reagent 
(Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s  protocol.  RNA  concentrations  were 
determined spectrophotometrically, and molecular 
integrity was checked by gel electrophoresis. RNA 
quality was confirmed using an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA).
Mature mirnA transfection and small interfering 
rnA treatment
The following RNA species were used in this study: 
mature miRNAs, Pre-miRTM miRNA Precursors (hsa-
miR-1; Pre-miR ID: PM10633), negative control miRNA 
(P/N: AM17111) (Applied Biosystems, Foster City, CA, 
USA), small interfering RNA (Stealth Select RNAi™ 
siRNA; si-TAGLN2 Cat#; HSS144745 and HSS144746) 
Figure 7: miR-1 and TAGLN2 mrnA expression 
levels in clinical specimens. (A) miR-1 expression in 
normal adjacent tissues and tumor tissues in 20 clinical 
specimens of HNSCC. (B) TAGLN2 mRNA expression 
in tumor tissues and normal adjacent tissues in 20 clinical 
HNSCC specimens.
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(Invitrogen)  and  negative  control  siRNA  (D-001810-
10;  Thermo  Fisher  Scientific,  Waltham,  MA,  USA). 
RNAs were incubated with Opti-MEM (Invitrogen) 
and LipofectamineTM RNAiMax reagent (Invitrogen) 
as described previously [11]. Transfection efficiency of 
Pre-miRTM in cell lines was confirmed based on down-
regulation of TWF1(PTK9) mRNA following transfection 
with miR-1 as previously reported [12,13,16].
cell proliferation, migration and invasion assays
Cells  were  transfected  with  10  nM  miRNA  and 
siRNA by reverse transfection and plated in 96 well 
plates at 3 x 103 cells per well. After 72 hr or 96 hr, cell 
proliferation was determined by the XTT assay, using the 
Cell Proliferation Kit II (Roche Molecular Biochemicals, 
Mannheim,  Germany)  [13,16].  Triplicate  wells  were 
measured for cell viability in each treatment group.
Cell migration activity was evaluated using a 
wound-healing assay. HSC3 was plated in six well plates 
at 2 x 105 cells per well, and the cell monolayers were 
scraped using a micropipette tip. The initial gap length 
(0 hr) and the residual gap length (24 hr after wounding) 
were calculated from photomicrographs [12]. FaDu was 
not suitable for the wound healing assay because the cell 
monolayer tended to peel off during scraping.
A cell invasion assay was carried out using modified 
Boyden  chambers  containing  transwell-precoated 
Matrigel membrane filter inserts with eight μm pores in 
24 well tissue culture plates at 1 x 105 cells per well (BD 
Biosciences,  Bedford,  MA,  USA)[12].  Triplicate  wells 
were measured for cell invasion in each treatment group.
Flow cytometry
HSC3 and FaDu cells transiently transfected with 
miRNA-control,  miR-1, siRNA-control and si-TAGLN2 
were harvested 72 hr after transfection by trypsinization. 
After the double staining with FITC-Annexin V and 
Propidium iodide (PI) was done using the FITC Annexin 
V Apoptosis Detection Kit (BD Biosciences) according 
to  the  manufacturer’s  recommendations,  the  cells 
were analyzed with a flow cytometry (FACScan®; BD 
Biosciences)  equipped  with  a  CellQuest  software  (BD 
Biosciences). Cells were discriminated into viable cells, 
dead cells, early apoptotic cells, and apoptotic cells, and 
then the relative ratio of early apoptotic cells to miRNA-
control transfectant from each experiment were compared. 
Cells for cell cycle analysis were stained with PI using the 
CycleTEST™ PLUS DNA Reagent Kit (BD Biosciences) 
following the protocol and analyzed by FACScan. The 
percentage  of  the  cells  in  G0/G1,  S,  and  G2/M  phase 
were counted and compared. Experiments were done in 
triplicate.
target gene search for mir-1
A genome-wide screen using miR-1 transfectants 
was performed to identify target genes of miR-1 in two 
HNSCC  cell  lines,  HSC3  and  FaDu.  Oligo-microarray 
human 44K (Agilent Technologies) was used for 
expression  profiling  of  the  transfectants  in  comparison 
with a miRNA-negative-control transfectant [12,13,16]. 
Hybridization  and  wash  steps  were  performed  as 
previously described [37]. The arrays were scanned using 
a Packard GSI Lumonics ScanArray 4000 (Perkin Elmer, 
Boston, MA, USA). The data were analyzed by means of 
DNASIS array software (Hitachi Software Engineering, 
Tokyo, Japan), which converted the signal intensity for 
each spot into text format. The log2 ratios of the median-
subtracted  background  intensities  were  analyzed.  Data 
from each microarray study were normalized by a global 
normalization method [37].
Predicted target genes and their target miRNA 
binding site seed regions were investigated using 
TargetScan  (release  5.1,  http://www.targetscan.org/). 
The sequences of the predicted mature miRNAs were 
confirmed using miRBase (release 16.0, http://microrna.
sanger.ac.uk/).
real-time quantitative rt-Pcr
First-strand  cDNA  was  synthesized  from  one  μg 
of  total  RNA  using  a  High  Capacity  cDNA  Reverse 
Transcription  Kit  (Applied  Biosystems).  Gene-specific 
PCR products were assayed continuously using a 7900-HT 
Real-Time PCR System according to the manufacturer’s 
protocol. The initial PCR step consisted of a ten min hold 
at 95°C, followed by 40 cycles consisting of a 15 sec 
denaturation at 95°C and a one min annealing/extension 
at 63°C. TaqMan® probes and primers for TAGLN2 (P/N: 
Hs00761239_s1)  and  the  GAPDH  (A/N:  NM_002046) 
internal control were obtained from Applied Biosystems 
(Assay-On-Demand  Gene  Expression  Products).  The 
expression levels of miR-1 (P/N: PM10617) were analyzed 
by  TaqMan  quantitative  real-time  PCR  (TaqMan® 
MicroRNA Assay; Applied Biosystems) and normalized 
to RNU48 (A/N: X96648). All reactions were performed 
in triplicate, and included negative control reactions that 
lacked cDNA.
Immunoblotting
Cells were harvested 72 hr after transfection and 
lysates  were  prepared.  Fifty  μg  of  protein  lysate  was 
separated by NuPAGE on 4 - 12% bis-tris gels (Invitrogen) 
and  transferred  to  PVDF  membranes.  Immunoblotting 
was performed with diluted (1:150) polyclonal TAGLN2 
antibody  (HPA001925;  Sigma-Aldrich,  St.  Louis,  MO, Oncotarget 2011; 2:  29 - 42 40 www.impactjournals.com/oncotarget
USA),  with  β-actin  antibody  (sc-1615;  Santa  Cruz 
Biotechnology, Santa Cruz, CA, USA) used as an internal 
control. The membrane was washed and incubated with 
goat  anti-mouse  IgG  (H+L)-HRP  conjugate  (Bio-Rad, 
Hercules, CA, USA). Specific complexes were visualized 
by echochemiluminescence (GE Healthcare Bio-Sciences, 
Princeton, NJ, USA), and the expression level of these 
genes was evaluated by ImageJ software (ver.1.43; http://
rsbweb.nih.gov/ij/index.html).
Plasmid construction and dual-luciferase assay
MiRNA target sequences were inserted between 
the  XhoI–PmeI  restriction  sites  in  the  3’UTR 
of the hRluc gene in the psiCHECK™-2 vector 
(C8021;  Promega,  Madison,  WI,  USA).  Primer 
sequences  for  full-length  3’UTR  of  TAGLN2  mRNA 
(ATCGCTCGAGACAGATGGGCACCAACCGCG and 
CTCTAGGTTTAAACATCTTCCTCAAGCCCCAGAC) 
were  designed.  Specific  miRNA  target  sequences  (71–
77:  atattttagcagtgacattcccagagagccccaga  gctct;  185-
191:  tcccccatgcttactaatacattcccttccccatagccat;  348-354: 
ctgagctctgtgtcctccgttcattccatggctgggagtc) for miR-1 
were artificially synthesized and inserted in the vector. 
Following that, HSC3 cells were transfected with 15 ng 
of vector, 10 nM of
miRNA,  and  one  μL  of  Lipofectamine™  2000 
(Invitrogen) in 100 μL of Opti-MEM™ (Invitrogen). The 
activities of firefly and Renilla luciferases in cell lysates 
were determined with a dual-luciferase assay system 
(E1910; Promega). Normalized data were calculated as 
quotients of Renilla/firefly Luciferase activities.
clinical Hnscc specimens
Twenty pairs of primary HNSCC (oral cavity, six; 
larynx,  three;  oropharynx,  five;  hypopharynx,  six)  and 
corresponding normal epithelial samples were obtained 
from patients in Chiba University Hospital (Chiba, Japan) 
from 2007 to 2009. All tissue specimens were obtained 
from patients undergoing surgical treatment. Normal 
tissues were obtained far from the center of the cancer 
in surgical specimens. No cancer cells were detected in 
neighboring  formalin-fixed  paraffin-embedded  tissues. 
Written consent of tissue donation for research purposes 
was obtained from each patient before tissue collection. 
The protocol was approved by the Institutional Review 
Board of Chiba University. The specimens were immersed 
in RNAlater (Qiagen, Valencia, CA, USA) and stored at 
-20°C until RNA was extracted.
statistical analysis
The relationships between two groups and the 
numerical values obtained by real-time RT-PCR were 
analyzed using the nonparametric Mann-Whitney U test 
or the paired t-test. The relationship among three variables 
and numerical values was analyzed using the Bonferroni-
adjusted Mann-Whitney U test; a non-adjusted statistical 
level  of  significance  of  P  <  0.05  corresponded  to  a 
Bonferroni-adjusted  level  of  P  <  0.0167. All  analyses 
were performed using Expert StatView (version 4, SAS 
Institute Inc., Cary, NC, USA).
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